Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mesenchymal Stem Cell Therapy in Long COVID
NCT06492798Phase 2Recruiting
- Sponsor
- Changhai Hospital
- Start
- Sep 2023
- Primary completion
- Jul 2025
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of human umbilical cord mesenchymal stem cells in post acute COVID-19 syndrome (2 arms), sponsored by Changhai Hospital. Primary endpoint: Common Terminology Criteria for Adverse Events at Day 28. Started Sep 2023; status: recruiting.
02
Drugs
human umbilical cord mesenchymal stem cells
03
Conditions
post acute COVID-19 syndrome
Beyond the preview
Go deeper on NCT06492798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06492798.